- Admin
- #1
Ozempic, Novo Nordisk's (NYSE: NVO) blockbuster drug for type 2 diabetes, is having all sorts of unexpected impacts on the healthcare sector. With the help of similar medicines made by Eli Lilly (NYSE: LLY), and expanded labels that allow the two companies to market formulations of those products for obesity, everyone from big pharmas to medical device manufacturers is trying to plan for a future in which it's easier for patients to lose weight.